Focus: AngioSafe is a San Jose-based biotechnology company specializing in cardio-intervention devices, with a focus on peripheral artery occlusion crossing systems. The company operates in a niche medical device segment within the broader cardiovascular and interventional therapy space.
Profile data last refreshed 6h ago · AI intelligence enriched 3w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
AngioSafe is a high-risk, high-reward early-stage device play best suited for entrepreneurs seeking equity upside and device development expertise in cardio-intervention, but not for those prioritizing cash stability or career signal strength.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AngioSafe
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AngioSafe's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles